Smith & Nephew PLC

Smith & Nephew’s shares climb modestly as FTSE 100 lifts, reflecting investor confidence in its global medical‑device business amid a supportive macro‑economic backdrop.

Smith & Nephew PLC’s shares surge 16% after a strong second quarter, driven by robust sales growth and a strategic $500 million share buyback program.

Smith & Nephew PLC has reported steady growth in its first quarter of 2025, despite facing challenges in China, and has reaffirmed its full-year outlook, demonstrating its resilience and strategic agility in the healthcare sector.

Smith & Nephew PLC reported steady revenue growth in Q1 2025, driven by operational improvements and new product launches, despite facing market challenges, and reaffirmed its full-year guidance.

Smith & Nephew PLC reported steady growth in Q1 2025, driven by operational improvements and new product launches, despite facing challenges in the Chinese market.

Smith & Nephew PLC has demonstrated resilience and strategic agility, reporting robust revenue growth in Q1 2025 despite market challenges, and positioning itself for sustained growth in the dynamic healthcare sector.

Smith & Nephew PLC reported steady revenue growth in Q1 2025, maintaining its full-year outlook despite market challenges, and its resilience is seen as a positive indicator for investors.

Smith & Nephew PLC reported a strong Q1 2025 revenue of $1.407 billion, demonstrating resilience and strategic foresight in the face of market challenges, including US tariffs and headwinds in China.

Smith & Nephew PLC has demonstrated resilience and strategic acumen, reporting a robust first quarter in 2025 and positioning itself for future success despite market challenges.

Smith & Nephew PLC reported a strong first quarter in 2025, driven by operational improvements and innovative product launches, positioning the company for sustained growth in the health care sector.